Masimo (NASDAQ:MASI) and CardioGenics (OTCMKTS:CGNH) Financial Comparison

Masimo (NASDAQ:MASI) and CardioGenics (OTCMKTS:CGNH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Volatility & Risk

Masimo has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, CardioGenics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.

Profitability

This table compares Masimo and CardioGenics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Masimo	-24.85%	26.54%	11.49%
CardioGenics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for Masimo and CardioGenics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0	1	5	0	2.83
CardioGenics	0	0	0	0	0.00

Masimo presently has a consensus target price of $193.60, suggesting a potential upside of 38.57%. Given Masimo’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Masimo is more favorable than CardioGenics.

Institutional and Insider Ownership

86.0% of Masimo shares are owned by institutional investors. 16.9% of Masimo shares are owned by insiders. Comparatively, 41.4% of CardioGenics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Masimo and CardioGenics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$2.09 billion	3.62	-$304.90 million	($8.52)	-16.40
CardioGenics	N/A	N/A	N/A	N/A	N/A

CardioGenics has lower revenue, but higher earnings than Masimo.

Summary

Masimo beats CardioGenics on 7 of the 10 factors compared between the two stocks.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.